ST吉药(300108) - 2016 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2016 was ¥140,997,924.29, a decrease of 14.35% compared to ¥164,619,738.85 in the same period last year[9] - Net profit attributable to shareholders was ¥30,894,061.22, down 10.09% from ¥34,361,722.62 year-on-year[9] - Basic earnings per share decreased by 40.25% to ¥0.0729 from ¥0.122 in the previous year[9] - The weighted average return on equity decreased to 1.88% from 2.28% year-on-year[9] - The company reported non-recurring losses totaling -¥677,905.62, primarily due to operational losses and donations[10] - The company's total profit available for distribution carried forward to future years is approximately 224.78 million yuan[31] - The total comprehensive income for Q1 2016 was ¥2,197,995.60, down from ¥3,911,355.41 in the same quarter last year[51] Cash Flow and Liquidity - The net cash flow from operating activities improved by 90.02%, reaching -¥68,880,880.57 compared to -¥76,527,815.27 in the same period last year[9] - Cash and cash equivalents decreased by 31.80% to ¥172,640,000.85 compared to the beginning of the year, primarily due to an increase in accounts receivable and prepayments[19] - Cash inflow from financing activities decreased by 60% to ¥40,000,000.00 compared to ¥100,000,000.00 in the previous year, primarily due to a reduction in bank loans[19] - Cash outflow from financing activities decreased by 37.10% to ¥48,444,163.44 from ¥77,014,277.78 in the previous year, mainly due to a decrease in bank loan repayments[19] - Cash and cash equivalents at the end of Q1 2016 were ¥172,640,200.85, compared to ¥147,268,777.95 at the end of Q1 2015[55] - The ending balance of cash and cash equivalents reached $40,375,212.54, up from $19,259,444.67 in the previous period[58] Assets and Liabilities - Total assets increased by 0.91% to ¥2,341,320,265.07 from ¥2,320,179,751.96 at the end of the previous year[9] - Current assets totaled approximately 980.95 million yuan, compared to 944.17 million yuan at the beginning of the period, reflecting an increase of about 3.5%[37] - Total liabilities decreased slightly to CNY 654,086,135.74 from CNY 661,843,721.10[41] - The company's equity attributable to shareholders increased to CNY 1,664,816,881.98 from CNY 1,636,585,183.33[41] Operational Efficiency - Operating costs increased by 16.76% to ¥83,399,889.61 compared to ¥100,193,760.41 in the previous year, primarily due to a decline in sales revenue from Jinbao Pharmaceutical[20] - The company plans to enhance management efficiency and innovation to mitigate risks associated with market competition and raw material price fluctuations[13] - The company plans to increase research and development of new products to enhance sales revenue[20] - The company is currently in the research phase for several new products, including specialized precipitated silica for various applications[21] Market Outlook - The company anticipates a market improvement in the next quarter, despite challenges from increased fixed asset depreciation and labor costs due to expanded production capacity[12] - Jinbao Pharmaceutical has become a subsidiary, expanding the company's asset scale and business scope, but integration challenges may impact operations[12] Investment Activities - Cash outflow from investment activities decreased by 67.75% to ¥3,168,089.53 from ¥9,823,946.20 in the same period last year, mainly due to reduced investment in construction projects[19] - The company reported a total cash outflow from investing activities of ¥3,168,089.53, compared to ¥9,823,946.20 in the previous year, showing a decrease of 67.8%[55] - Investment cash outflow was recorded at $881,972.63, with no cash inflow reported for investment activities[58] Shareholder Returns - The company reported a cash dividend of 1 yuan per 10 shares, totaling approximately 424 million shares, with a distribution plan pending approval at the 2015 annual general meeting[31]